India has emerged as one of the most competitive and strategically important destinations for CDMO pharmaceutical services. Today, global drug manufacturers rely on India due to its unmatched combination of cost efficiency, advanced capabilities, and strong compliance culture. As the demand for end-to-end CDMO pharma solutions grows, India’s position as a global benchmark setter is stronger than ever.
One of India’s greatest advantages is cost competitiveness without compromising quality. Decades of expertise, economies of scale, and efficient operating models enable Indian CDMOs to manufacture high-quality products at significantly lower costs than Western counterparts. This cost advantage is particularly valuable for innovators seeking commercial scalability.
Next is the advantage of capability diversity. India offers one of the widest ranges of dosage forms globally—oral solids, liquids, injectables, ointments, ophthalmics, nutraceuticals, biologics, herbal products, and complex generics. This breadth supports a wide spectrum of therapeutic goals and market requirements.
The third pillar of India’s CDMO strength is regulatory compliance. Indian manufacturers follow global quality frameworks and have successfully cleared audits from WHO, USFDA, MHRA, ANVISA, EMA, and other regulatory bodies. This compliance maturity allows global companies to trust India with high-value and sensitive products.
The fourth advantage is India’s skilled pharmaceutical workforce. With decades of scientific and technical training, Indian professionals have become global leaders in formulation development, scale-up, biotechnology, and quality assurance. This talent pool enables India’s CDMOs to achieve faster, more efficient outcomes.
Within India’s strong CDMO landscape, Akums stands as one of the benchmark-setting companies. As one of the largest players in the country, Akums brings unmatched scale, quality consistency, and technical depth to the global CDMO market. With a strong export footprint and approvals across regulated, semi-regulated, and emerging markets, Akums supports partners across the world.
The company’s extensive portfolio includes 4,000+ commercialised formulations, making it one of the most diverse product libraries in the country. Akums also serves a 1,500+ client base, including leading pharma companies from India and global regions. Its end-to-end capabilities—from development to large-scale manufacturing—place it among the Best CDMO in India.
Akums’ world-class capabilities are supported by automated systems, digital QMS tools, and stringent compliance mechanisms. Whether in oral solids, injectables, nutraceuticals, derma-cosmeceuticals, or herbal formulations, Akums delivers consistent performance across product categories.
India’s CDMO advantage is further enhanced by government support, policy reforms, and investments in Make in India-led initiatives. With rising interest from global pharmaceutical companies and the increasing complexity of drug development, India’s CDMOs are positioning themselves as innovation-driven powerhouses.
As the future of global healthcare demands agility, capability, and cost-effective solutions, India will continue to attract partners seeking sustainable, compliant, and scalable CDMO collaborations. Companies like Akums, with their unmatched scale and reliability, will play a leading role in shaping India’s global pharmaceutical leadership.
